All In Biotech

Drug Trial Radar · NCT03694522

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1

Last checked: Nov 19, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

155

Actual

Start

Sep 14, 2018

Primary completion

Sep 23, 2020

Study completion May 13, 2022

Sponsor

Lead sponsor
Five Prime Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Zai Lab (Shanghai) Co., Ltd.
First posted
Oct 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.

Conditions

  • Gastric Cancer

Interventions

  • BemarituzumabBiological

    Administered by intravenous infusion over approximately 30 minutes

  • PlaceboDrug

    Administered by intravenous infusion over approximately 30 minutes

  • Modified FOLFOX6Drug

    mFOLFOX6 regimen consists of the following: * Oxaliplatin 85 mg/m² IV infusion over 120 minutes * Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable * 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From randomization until the primary analysis data cut-off date of 23 September 2020; median time on follow-up was 10.9 months.

Locations

189 sites in 18 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center

    Tucson, Arizona

  • The Oncology Institute of Tuscon

    Tucson, Arizona

  • Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc

    Greenbrae, California

  • Sutter Medical Group

    Sacramento, California

  • UCLA Medical Centre - Santa Monica Hematology and Oncology

    Santa Monica, California

  • Innovative Clinical Research Institute (ICRI)

    Whittier, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut

    Plainville, Connecticut

  • University of Chicago

    Chicago, Illinois

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois

  • University of Kansas Medical Center

    Westwood, Kansas

  • Oschsner Clinic Foundation

    New Orleans, Louisiana

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Josephine Ford Cancer Center-Henry Ford Cancer Center

    Detroit, Michigan

  • Summit Medical Group. Morristown Oncology

    Morristown, New Jersey

  • University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)

    Rochester, New York

  • Stony Brook Cancer Center

    Stony Brook, New York

  • Westchester Institute For Treatment Of Cancer & Blood Disorders

    White Plains, New York

  • UNC- Chapel Hill

    Chapel Hill, North Carolina

  • FirstHealth Outpatient Cancer Center

    Pinehurst, North Carolina

  • St. Luke's Physician Group - St. Luke's Cancer Care Associates

    Bethlehem, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Tennessee Cancer Specialists

    Knoxville, Tennessee

  • Arlington Cancer Center

    Arlington, Texas

  • Utah Cancer Specialists (Intermountain Hematology - Oncology Associates) UCS Cancer Center

    South Salt Lake, Utah

  • Virginia Mason Seattle Main Clinic

    Seattle, Washington

  • Chris O'brien Lifehouse

    Camperdown, Australia

  • The Townsville Hospital

    Douglas, Australia

  • Sydney Adventist Hospital

    Wahroonga, Australia

  • AZ Sint Jan

    Bruges, Belgium

  • CH de l'Ardenne

    Libramont, Belgium

  • CHC Clinique Saint-Joseph

    Liège, Belgium

  • CHU UCL Namur, site Godinne

    Yvoir, Belgium

  • Beijing Cancer Hospital

    Beijing, China

  • Chinese PLA General Hospital

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • Sino Japanese Friendship Hospital of Jilin University

    Changchun, China

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.